| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.18▼ | 0.19▼ | 0.19▼ | 0.19▼ | 0.22▼ |
| MA10 | 0.19▼ | 0.20▼ | 0.20▼ | 0.19▼ | 0.23▼ |
| MA20 | 0.20▼ | 0.20▼ | 0.19▼ | 0.20▼ | 0.24▼ |
| MA50 | 0.19▼ | 0.19▼ | 0.19▼ | 0.23▼ | 0.25▼ |
| MA100 | 0.19▼ | 0.20▼ | 0.21▼ | 0.23▼ | 0.40▼ |
| MA200 | 0.20▼ | 0.23▼ | 0.23▼ | 0.23▼ | 0.73▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | -0.003▼ | -0.002▼ | 0.001▲ | -0.004▼ |
| RSI | 35.597▼ | 37.456▼ | 40.359▼ | 42.424▼ | 42.262▼ |
| STOCH | 0.419▼ | 0.261▼ | 7.954▼ | 47.315 | 21.315 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -55.556 | -88.636▼ |
| CCI | -81.823 | -120.973▼ | -146.332▼ | -3.332 | -131.358▼ |
|
Tuesday, February 25, 2020 11:33 PM
NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") announced today that it is expanding its CD33 program studying Actimab-A into a combination trial ...
|
|
Monday, April 01, 2019 07:10 AM
Actinium Pharmaceuticals Inc (NYSE: ATNM) will present Phase 2 data for Actimab-A in acute myeloid leukemia at the international symposium on TAT. Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 03/04/20 | 0.195 | 0.195 | 0.18 | 0.189 | 1,028,200 |
| 02/04/20 | 0.19 | 0.19 | 0.18 | 0.18 | 548,652 |
| 01/04/20 | 0.194 | 0.195 | 0.183 | 0.187 | 1,000,500 |
| 31/03/20 | 0.214 | 0.214 | 0.192 | 0.194 | 1,210,800 |
| 30/03/20 | 0.20 | 0.205 | 0.187 | 0.201 | 2,337,200 |
| 27/03/20 | 0.19 | 0.197 | 0.182 | 0.197 | 1,204,100 |
| 26/03/20 | 0.183 | 0.194 | 0.179 | 0.189 | 1,510,200 |
| 25/03/20 | 0.19 | 0.195 | 0.182 | 0.187 | 1,694,400 |
| 24/03/20 | 0.182 | 0.20 | 0.182 | 0.193 | 1,228,900 |
| 23/03/20 | 0.175 | 0.193 | 0.175 | 0.18 | 1,853,800 |
|
|
||||
|
|
||||
|
|